SCHEMBL496738

SCHEMBL496738

O=S(=O)(O)Cc1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 3/20 0.51
MAPT P10636 2/20 0.51
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
PNMT P11086 1/20 0.46
IDO1 P14902 1/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
AKR1B1 P15121 1/20 0.46
PKM P14618 1/20 0.44
KCNJ5 P48544 1/20 0.44
KCNJ3 P48549 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28130066 0.98 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL2907991 0.85 PNMT (0.54) ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A
SCHEMBL10398011 0.84 TSHR (0.42) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL4013559 0.83 PNMT (0.52) ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A
SCHEMBL4013563 0.83 PNMT (0.52) ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A
SCHEMBL1194386 0.82 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL11757162 0.81 TSHR (0.40) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL5963 0.80 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL3028541 0.80 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL11831456 0.79 ALDH1A1 (0.41) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492390-B2 Synthesis of locked nucleic acid derivatives SANTARIS PHARMA A/S (DK) 2013-07-23 US claimed
EP-2578577-A1 Sulfonyl esters of tetrahydrocannabinol and derivatives thereof Albany Molecular Research, Inc. (US) 2013-04-10 EP claimed
US-8084458-B2 Synthesis of locked nucleic acid derivatives SANTARIS PHARMA A/S (DK) 2011-12-27 US claimed
US-20100216983-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES SANTARIS PHARMA A/S, a Denmark corporation 2010-08-26 US claimed
US-7674922-B2 Process for production of delta-9-tetrahydrocannabinol ALBANY MOLECULAR RESEARCH, INC. (US) 2010-03-09 US claimed
US-7569575-B2 Formed via intermediates which are reactive with nucleophiles SANTARIS PHARMA A/S (DK) 2009-08-04 US claimed
EP-1928853-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR Technology, Inc. (US) 2008-06-11 EP claimed
EP-1501848-B1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES SANTARIS PHARMA AS (DK) 2007-08-08 EP claimed
US-20070093665-A1 Process for production of delta-9- tetrahydrocannabinol AMR TECHNOLOGY, INC. (US) 2007-04-26 US claimed
WO-2007041167-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR TECHNOLOGY, INC. (US) 2007-04-12 WO claimed
EP-1163250-B1 IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES EXIQON AS (DK) 2006-07-12 EP claimed
EP-1501848-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES Santaris Pharma A/S (DK) 2005-02-02 EP claimed
US-20040014959-A1 Synthesis of locked nucleic acid derivatives SANTARIS PHARMA A/S (DK) 2004-01-22 US claimed
WO-2003095467-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES SANTARIS PHARMA A/S (DK) 2003-11-20 WO claimed
CN-109233322-B Blue acid dye and preparation method thereof 绍兴金美珂化工有限公司 2020-04-07 CN disclosed
US-9783534-B2 Crystalline form of 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1, 3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenylmethanesulphonate BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2017-10-10 US disclosed
US-20160251344-A1 Novel crystalline form of 2-piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenylmethanesulphonate BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-09-01 US disclosed
WO-1990002731-A1 PROCESS FOR THE PREPARATION OF 4-SULFO-2-CHLOROBENZOIC ACID INTEROX CHEMICALS LIMITED (GB) 1990-03-22 WO disclosed
US-4415574-A BACTERICIDES; MEDICINES; POTENTIATION OF SULFA DRUGS S. A. PANMEDICA (FR) 1983-11-15 US disclosed
US-4139530-A CATIONIC DYES BAYER AKTIENGESELLSCHAFT (DE) 1979-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216983-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES RNGTT, NSUN3, NSUN2 ALDH1A1 1716/4885KDM4E 2204/4885MAPT 2218/4885
US-20070093665-A1 Process for production of delta-9- tetrahydrocannabinol CNR2, CNR1, HRH4 ALDH1A1 2849/4885KDM4E 2374/4885MAPT 2643/4885
US-20040014959-A1 Synthesis of locked nucleic acid derivatives NSUN3, RNGTT, NSUN2 ALDH1A1 1589/4885KDM4E 2081/4885MAPT 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.